

RE: Expiry Date Extension of CeeNU (lomustine) lots

Dear Healthcare Professional,

Bristol Myers Squibb would like to inform you that Health Canada has approved a 6-month expiry date extension for existing product lots of CeeNU (lomustine). The current lots in distribution will be safe to use for an **additional six (6) months** beyond the expiry date printed on the product label.

Product / Strength	DIN	Lot	Expiry date printed Label	Approved Extended Expiry Date
CeeNU 10mg	00360430	2H02104 2H02101	2025 / 05	2025 / 11
CeeNU 40mg	00360422	2J06575 2J06574	2025 / 06	2025 / 12

The decision to extend the expiry date of CeeNU, based on the analysis of stability data, provides confidence that the product can be safely used beyond the printed date on the label.

It is to be noted that there could be a potential slight decrease in the potency of CeeNU 40mg lots 2J06575 and 2J06574 at the extended expiry date (although very unlikely) without any additional safety concerns.

Please refer to Health Canada's Supply Notice: <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-shortages/information-consumers/supply-notices/ceenu-lomustine-canada.html>

Indication:

CeeNU (lomustine-CCNU) is indicated as palliative therapy in addition to surgery and radiotherapy or in combination therapy with other chemotherapeutic agents in the following:

- Brain tumours - both primary and metastatic, in patients who have already received appropriate surgical and/or radiotherapeutic procedures.
- Hodgkin's Disease - as a secondary therapy, alone or in combination with other active drugs.
- Other Tumours - CeeNU has been used in combination with other therapeutic agents in lung cancer (squamous cell, anaplastic large cell, and adenocarcinoma), malignant melanoma and breast cancer (advanced disease) only after other conventional methods have failed.

You can report any suspected adverse reactions associated with the use of health products to Health Canada by: Calling toll-free at 1-866-234-2345; or Visiting MedEffect Canada's Web page on Adverse Reaction Reporting (<http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index-eng.php>) for information on how to report online, by mail or by fax.

If you have questions or require additional information regarding CeeNU, please contact Bristol Myers Squibb Canada at 1-800-267-0005 or via e-mail at otc.canada@bms.com.

For medical information requests, please contact our Medical Information Services at 1-866- 463-6267 or at medical.canada@bms.com.

Sincerely,



Franck Chenu, PharmD, PhD
Country Medical Director
BMS Canada